Literature DB >> 5165732

Interaction of some daunomycin derivatives with deoxyribonucleic acid and their biological activity.

A Di Marco, F Zunino, R Silverstrini, C Gambarucci, R A Gambetta.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5165732     DOI: 10.1016/0006-2952(71)90365-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  14 in total

1.  Synthesis of a lipophilic daunorubicin derivative and its incorporation into lipidic carriers developed for LDL receptor-mediated tumor therapy.

Authors:  A J Versluis; E T Rump; P C Rensen; T J Van Berkel; M K Bijsterbosch
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

2.  The persistence of adriamycin in man and rat.

Authors:  P M Wilkinson; G E Mawer
Journal:  Br J Clin Pharmacol       Date:  1974-06       Impact factor: 4.335

Review 3.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 4.  Topoisomerase inhibitors. A review of their therapeutic potential in cancer.

Authors:  B K Sinha
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

Review 5.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

6.  Daunomycin inhibits the B leads to Z transition in poly d(G-C).

Authors:  J B Chaires
Journal:  Nucleic Acids Res       Date:  1983-12-10       Impact factor: 16.971

7.  Antitumor activity of new anthracycline analogues in combination with interferon alfa.

Authors:  M E Berens; T Saito; C E Welander; E J Modest
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

8.  Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients.

Authors:  S O Nilsson; B Andersson; S Eksborg; M Beran; H Ehrsson
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

9.  Anthracycline cardiomyopathy.

Authors:  N L Kobrinsky; N K Ramsay; W Krivit
Journal:  Pediatr Cardiol       Date:  1982       Impact factor: 1.655

10.  The limited role of corticosteroids in ameliorating experimental doxorubicin skin toxicity in the mouse.

Authors:  R T Dorr; D S Alberts; H S Chen
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.